
Opinion|Videos|January 8, 2025
Recent Safety and Efficacy Updates from the Investigator Initiated Study of Loncastuximab tesirine + Rituximab for the Treatment of R/R FL
Author(s)Juan Pablo Alderuccio, MD
A panelist discusses updates from from the phase 2 study of loncastuximab + rituximab from ASH 2024.
Advertisement
Episodes in this series

Video content above is prompted by the following:
- Discuss the updated results from the phase 2 study of loncastuximab + rituximab in R/R FL presented at ASH 2024
- What were the key efficacy results, what about the safety profile?
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Oncology Update January 2026: New Horizons in Precision Medicine
2
Gemogenovatucel-T Triples Overall Survival in High-Risk HRP Ovarian Cancer
3
CD47 Expression Serves as Predictive Biomarker for HER2+ Breast Cancer
4
FDA Grants Orphan Drug Designation to IFx-2.0 for Advanced Melanoma
5



















